Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Age
40–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Willingness to sign a written informed consent
Chronic obstructive pulmonary disease (COPD) according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines 2009
Chinese or Malay or Indian ethnicity
History of chronic obstructive pulmonary disease symptoms for at least 12 months prior to baseline visit V0
Forced expiratory volume in the first second/ Forced vital capacity (FEV1/FVC) ratio (post-bronchodilator) \< 70%
Forced expiratory volume in the first second (FEV1) (post-bronchodilator) \< 50 % of predicted
Former smoker (defined as: smoking cessation at least one year ago) or current smoker both with a smoking history of at least 10 pack years
You may not be if
Moderate or severe COPD exacerbation and/or COPD exacerbations treated with antibiotics not stopped at V0
Lower respiratory tract infection not resolved 4 weeks prior to the baseline visit V0
History of asthma diagnosis in patients \< 40 years of age or relevant lung disease other than COPD
Current participation in a pulmonary rehabilitation program or completion of a pulmonary rehabilitation program within 3 months preceding the baseline visit V0
Known alpha-1-antitrypsin deficiency
Clareo Health | A Chronic Obstructive Pulmonary Disease (COPD) Trial Investigating Roflumilast on Safety and Effectiveness in China, Hong Kong and Singapore:
